D-ribose
What studies of d-ribose found
At a glance, by condition
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 5 findings, all C.
5 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: D-ribose might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- D-ribose · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Symptoms
Cognition (brain fog)1 study · 36 people took d-ribose Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (36 in all).
Studies with no comparison group41 in the study · 36 with outcome data · 25 days (range, 17 to 35 days · 5 g t.i.d, three times per day (t.i.d.)
Cognition (brain fog) improved.
The evidence is very uncertain about the effect of D-ribose on cognition (brain fog) in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (36 in all)
See the 1 study
-
The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. (2006)
- People in the study
- 41 in the study · 36 with outcome data
- Dose
- 5 g t.i.d, three times per day (t.i.d.)
- Outcome
- Mental clarity discrete Visual Analog Scale
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 36 people took d-ribose Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (36 in all).
Studies with no comparison group41 in the study · 36 with outcome data · 25 days (range, 17 to 35 days · 5 g t.i.d, three times per day (t.i.d.)
Fatigue improved.
The evidence is very uncertain about the effect of D-ribose on fatigue in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (36 in all)
See the 1 study
-
The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. (2006)
- People in the study
- 41 in the study · 36 with outcome data
- Dose
- 5 g t.i.d, three times per day (t.i.d.)
- Outcome
- Energy level discrete Visual Analog Scale
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Pain1 study · 36 people took d-ribose Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (36 in all).
Studies with no comparison group41 in the study · 36 with outcome data · 25 days (range, 17 to 35 days · 5 g t.i.d, three times per day (t.i.d.)
Pain improved.
The evidence is very uncertain about the effect of D-ribose on pain in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (36 in all)
See the 1 study
-
The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. (2006)
- People in the study
- 41 in the study · 36 with outcome data
- Dose
- 5 g t.i.d, three times per day (t.i.d.)
- Outcome
- Pain discrete Visual Analog Scale
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Sleep1 study · 36 people took d-ribose Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (36 in all).
Studies with no comparison group41 in the study · 36 with outcome data · 25 days (range, 17 to 35 days · 5 g t.i.d, three times per day (t.i.d.)
Sleep improved.
The evidence is very uncertain about the effect of D-ribose on sleep in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (36 in all)
See the 1 study
-
The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. (2006)
- People in the study
- 41 in the study · 36 with outcome data
- Dose
- 5 g t.i.d, three times per day (t.i.d.)
- Outcome
- Sleep discrete Visual Analog Scale
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Overall symptoms1 study · 36 people took d-ribose Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (36 in all).
Studies with no comparison group41 in the study · 36 with outcome data · 25 days (range, 17 to 35 days · 5 g t.i.d, three times per day (t.i.d.)
Overall symptoms improved.
The evidence is very uncertain about the effect of D-ribose on overall symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (36 in all)
See the 1 study
-
The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. (2006)
- People in the study
- 41 in the study · 36 with outcome data
- Dose
- 5 g t.i.d, three times per day (t.i.d.)
- Outcome
- Well-being discrete Visual Analog Scale
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Side effects
Side effects studies reported3 kinds
| Side effect | Studies that reported it |
|---|---|
| Anxiety or irritability | 1 study |
| Dizziness | 1 study |
| Nausea or stomach upset | 1 study |
All papers
- The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study.2006 · no comparison group · 41 in the study · 36 with outcome data
Summary
This open-label uncontrolled pilot study enrolled 41 adult patients diagnosed by their physicians as having FMS and/or CFS, recruited through an FMS and CFS e-mail newsletter and website. Patients were instructed to take one scoop (5-g) of D-ribose three times per day (t.i.d.) mixed with food, water, or another beverage until the 280-g container was empty; the average length of time on D-ribose was 25 days (range, 17 to 35 days). Five of 41 enrolled patients were considered noncompliant and excluded, leaving 36 in the final analysis. Patients completed discrete visual analog scales for energy, sleep, mental clarity, pain, and well-being before and at completion, plus a global subjective rating. In the 36 analysed patients, mean scores improved from 3.8 to 5.5 for energy, 4.8 to 6.0 for sleep, 4.9 to 5.7 for mental clarity, 4.9 to 5.6 for pain, and 4.3 to 5.6 for well-being. Twenty-three of 35 patients (65.7%) completing the assessment reported improvement (somewhat better to much better). Of five noncompliant patients, three stopped taking D-ribose because of a hyperanxious feeling (one patient), lightheadedness (one patient), and increased appetite (one patient); among 36 completers, one patient experienced transient nausea and another felt mild anxiety, both reversed by lowering the dose. The authors state limitations including lack of a placebo group, no clinic visits, subjective outcomes only, and continuation of other stable treatments.
- HERV Dysregulation in a Case of Myalgic Encephalomyelitis and Multiple Sclerosis Responsive to Rituximab.2025 · case report
Summary
This case report describes a single male patient in his 30s with a co-diagnosis of ME/CFS and MS, followed longitudinally. After a new MS relapse with radiological inflammation, he received rituximab at 1 g on days 1 and 15 of the first month, then nine monthly doses of 1 g adjusted by B-cell repopulation, a 9-month treatment regime. There was no comparison group; outcomes were before-versus-after observations in this patient. The report states a significant improvement in fatigue after the third dose, enabling increased mobility and participation in daily activities such as walking and dining out. On the Bell scale for severity assessment, the patient changed from a level of 10 to 20. After treatment he could leave the house 2–3 times a week and take gentle walks for an hour, and he reported a migraine once a month. The authors report he stayed in remission for at least 3 years after treatment. Harms of rituximab were not reported. The authors note limitations including sub-optimal frequency of MRI to monitor lesion progression and of HERV reassessment after rituximab, and the limited external validity of single study cases.
- Nutraceutical Supplementation Effects on Subjective Fatigue Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review.2025 · systematic review
Summary
Review authors searched ClinicalTrials.gov, Medline, PubMed, Cochrane and Web of Science for interventional studies of nutraceuticals or diet in adults with ME/CFS and included 14 studies, described as randomised controlled trials and open-label pilot trials. Interventions included CoQ10 (alone or with alpha-lipoic acid, NADH or selenium), NADH, melatonin with zinc, anhydrous enol-oxaloacetate, sodium dichloroacetate, hydrogen water, Ginkgo with Cistanche, guanidinoacetic acid, 6-methylsulfinylhexyl isothiocyanate, D-ribose, porcine serum polypeptide and probiotics, given for varying durations, with fatigue measured by self-report scales. CoQ10 plus alpha-lipoic acid lowered FSS scores (p < 0.0001); CoQ10 plus NADH lowered FIS-40 (p = 0.03; p < 0.001) and maximum HR (p = 0.022), with pain and sleep not significant; CoQ10 plus selenium lowered FIS-40 (p = 0.021); melatonin with zinc lowered FIS-40 (p < 0.05) without improving sleep or anxiety; probiotics improved the mental component (p = 0.043). Fatigue was not significant with guanidinoacetic acid, or with 6-MSITC on the CFQ-11. Reported side effects included dyspepsia (2/23 at 500 mg BID and 2/24 at 1,000 mg BID) and insomnia (1/26) with enol-oxaloacetate, epigastralgia and dizziness, tremor in one patient, and symptom flare-up in one patient. A meta-analysis was not conducted.
- Role of dietary modification in alleviating chronic fatigue syndrome symptoms: a systematic review.2017 · systematic review
Summary
This systematic review asked whether dietary modification alleviates chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME) symptoms. It searched Scopus, CINAHL Plus, Web of Science and PsycINFO from 1994 to 2014 in May 2014, with an update from June 2014 to August 2016, and included 22 studies across animal and human designs. Treatments included D-ribose, probiotic, oral vitamin D3, vitamin and mineral supplements, polynutrient supplementation, magnesium, calcium, ginseng, EFA supplements, glutamine, a low-sugar low-yeast diet, and polyphenols (AMF, EGCG, naringin). D-ribose showed significant improvement in energy levels in compliant analysis (p<0.0001, 95%CI 1.1–2.2), and 65.7% reported improved overall subjective feelings. Probiotic: six of 15 reported subjective improvement and neurocognitive measures improved (p=0.04), but no significant overall change. Vitamin D3 showed no statistically significant improvement in fatigue or inflammatory/oxidative markers. One vitamin/mineral supplement showed improvements in fatigue (p=0.0009) and some quality-of-life measures; another found no significant relationship. Polynutrient supplementation found no significant results. Magnesium improved fatigue at six months (p=0.002) but not at two years; calcium improved fatigue (p=0.01) based on five participants; ginseng was most helpful in 56%. An EFA case study dropped depression scores from 27 to 3 at 16 weeks; an EFA versus sunflower-oil placebo trial found no significant difference. Glutamine showed no significant symptom change; placebo showed decreases in emotionality and sleep problems (p=0.02). The low-sugar low-yeast diet showed no significant difference. Animal polyphenol studies reported significant improvements (p<0.05). The review did not report side effects or withdrawals.